MACROGENICS, INC. (MGNX) Spending and interest coverage
- R&D / revenue · 12 months: Value 80.18%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 6.18%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 80.18% | Research and development expense / revenue. Period ending 2026-06-30. $140.44M ÷ $175.14M × 100 ≈ 80.18% |
| Stock-based compensation / revenue · 12 months | 6.18% | Share-based compensation / revenue. Period ending 2026-06-30. $10.83M ÷ $175.14M × 100 ≈ 6.18% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 140.44M USD | Research and Development Expense |
| Revenue | 175.14M USD | |
| Stock-based compensation | 10.83M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -38.06M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $140.44M | $175.14M | $10.83M | $-38.06M | (m) | 80.18% | 6.18% | (m) | (m) |
| 2026-03-31 | $142.45M | $157.08M | $12.55M | $-63.66M | (m) | 90.68% | 7.99% | (m) | (m) |
| 2025-12-31 | $147.17M | $149.50M | $14.29M | $-72.84M | (m) | 98.44% | 9.56% | (m) | (m) |
| 2025-09-30 | $152.09M | $127.63M | $22.89M | $-113.58M | $4.21M | 119.17% | 17.94% | -26.97× | Reported |
| 2025-06-30 | $159.92M | $165.50M | $25.31M | $-78.03M | $870.00K | 96.63% | 15.29% | -89.69× | Reported |
| 2025-03-31 | $170.86M | $154.05M | $28.27M | $-99.45M | $73.00K | 110.91% | 18.35% | -1362.36× | Reported |
| 2024-12-31 | $177.19M | $149.96M | $29.44M | $-110.58M | $1.11M | 118.16% | 19.63% | -99.17× | Reported |
| 2024-09-30 | $185.66M | $141.33M | $22.53M | $-107.09M | $1.14M | 131.36% | 15.94% | -94.03× | Reported |
| 2024-06-30 | $175.24M | $41.02M | $21.35M | $-196.79M | $1.14M | 427.23% | 52.06% | -172.77× | Reported |
| 2024-03-31 | $166.74M | $43.36M | $19.09M | $-183.57M | $1.91M | 384.57% | 44.04% | -96.26× | Reported |
| 2023-12-31 | $166.58M | $58.75M | $18.37M | $-168.24M | $1.43M | 283.55% | 31.27% | -117.65× | Reported |
| 2023-09-30 | $164.89M | $121.13M | $18.75M | $-106.91M | (m) | 136.13% | 15.48% | (m) | (m) |
| 2023-06-30 | $182.94M | $152.47M | $19.09M | $-96.36M | (m) | 119.99% | 12.52% | (m) | (m) |
| 2023-03-31 | $191.46M | $165.34M | $20.00M | $-93.21M | (m) | 115.80% | 12.09% | (m) | (m) |
| 2022-12-31 | $207.03M | $151.94M | $20.44M | $-121.42M | (m) | 136.25% | 13.45% | (m) | (m) |
| 2022-09-30 | $217.23M | $92.99M | $21.11M | $-191.64M | (m) | 233.60% | 22.70% | (m) | (m) |
| 2022-06-30 | $218.86M | $66.92M | $22.34M | $-219.67M | (m) | 327.06% | 33.39% | (m) | (m) |
| 2022-03-31 | $222.89M | $71.67M | $23.11M | $-218.14M | (m) | 311.01% | 32.25% | (m) | (m) |
| 2021-12-31 | $214.58M | $77.45M | $23.13M | $-202.79M | (m) | 277.06% | 29.86% | (m) | (m) |
| 2021-09-30 | $201.02M | $115.99M | $22.97M | $-146.73M | (m) | 173.31% | 19.80% | (m) | (m) |
| 2021-06-30 | $195.86M | $118.58M | $22.45M | $-129.88M | (m) | 165.17% | 18.93% | (m) | (m) |
| 2021-03-31 | $197.43M | $108.08M | $21.47M | $-136.91M | (m) | 182.67% | 19.87% | (m) | (m) |
| 2020-12-31 | $193.20M | $104.88M | $20.68M | $-131.06M | (m) | 184.21% | 19.71% | (m) | (m) |
| 2020-09-30 | $202.86M | $77.38M | $20.91M | $-167.54M | (m) | 262.14% | 27.02% | (m) | (m) |
| 2020-06-30 | $203.05M | $77.87M | $20.48M | $-169.35M | (m) | 260.75% | 26.29% | (m) | (m) |
| 2020-03-31 | $197.14M | $68.21M | $20.26M | $-175.01M | (m) | 289.03% | 29.71% | (m) | (m) |
| 2019-12-31 | $195.31M | $64.19M | $19.57M | $-177.19M | (m) | 304.28% | 30.49% | (m) | (m) |
| 2019-09-30 | $190.28M | $54.79M | $18.43M | $-180.21M | (m) | 347.28% | 33.64% | (m) | (m) |
| 2019-06-30 | $191.64M | $56.85M | $17.61M | $-177.27M | (m) | 337.12% | 30.97% | (m) | (m) |
| 2019-03-31 | $192.22M | $65.09M | $16.89M | $-168.61M | (m) | 295.32% | 25.94% | (m) | (m) |
| 2018-12-31 | $190.83M | $60.12M | $16.52M | $-171.21M | (m) | 317.40% | 27.48% | (m) | (m) |
| 2018-09-30 | $182.89M | $196.69M | $15.85M | $-24.56M | (m) | 92.98% | 8.06% | (m) | (m) |
| 2018-06-30 | $177.65M | $177.55M | $15.28M | $-37.28M | (m) | 100.06% | 8.60% | (m) | (m) |
| 2018-03-31 | $160.10M | $160.38M | $14.71M | $-34.15M | (m) | 99.82% | 9.17% | (m) | (m) |
| 2017-12-31 | $147.23M | $157.74M | $14.74M | $-22.14M | (m) | 93.34% | 9.35% | (m) | (m) |
| 2017-09-30 | $139.35M | $10.49M | $14.10M | $-162.35M | (m) | 1328.58% | 134.46% | (m) | (m) |
| 2017-06-30 | $128.67M | $12.08M | $13.10M | $-148.89M | (m) | 1065.04% | 108.47% | (m) | (m) |
| 2017-03-31 | $127.55M | $91.09M | $12.63M | $-67.62M | (m) | 140.02% | 13.86% | (m) | (m) |
| 2016-12-31 | $122.09M | $91.88M | $12.16M | $-60.04M | (m) | 132.88% | 13.24% | (m) | (m) |
| 2016-09-30 | $121.03M | $94.95M | $11.34M | $-53.38M | (m) | 127.46% | 11.94% | (m) | (m) |
| 2016-06-30 | $114.83M | $106.38M | $10.44M | $-34.56M | (m) | 107.95% | 9.81% | (m) | (m) |
| 2016-03-31 | $104.15M | $32.42M | $9.22M | $-95.95M | (m) | 321.25% | 28.43% | (m) | (m) |
| 2015-12-31 | $98.27M | $100.85M | $7.85M | $-20.18M | (m) | 97.44% | 7.78% | (m) | (m) |
| 2015-09-30 | $87.88M | $98.15M | $6.63M | $-10.62M | (m) | 89.53% | 6.75% | (m) | (m) |
| 2015-06-30 | $82.41M | $101.85M | $5.38M | $895.00K | (m) | 80.91% | 5.29% | (m) | (m) |
| 2015-03-31 | $77.08M | $104.36M | $4.26M | $9.93M | (m) | 73.86% | 4.09% | (m) | (m) |
| 2014-12-31 | $70.19M | $47.80M | $3.24M | $-38.31M | (m) | 146.84% | 6.79% | (m) | (m) |
| 2014-09-30 | $64.88M | $57.23M | $2.72M | $-22.50M | (m) | 113.38% | 4.75% | (m) | (m) |
| 2014-06-30 | $57.34M | $59.08M | $2.00M | $-11.42M | (m) | 97.06% | 3.38% | (m) | (m) |
| 2014-03-31 | $51.05M | $62.16M | $1.33M | $588.89K | (m) | 82.14% | 2.14% | (m) | (m) |
| 2013-12-31 | $46.58M | $58.03M | $862.16K | $365.98K | (m) | 80.27% | 1.49% | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $48.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $53.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $45.43M | $63.83M | $838.39K | $8.21M | (m) | 71.18% | 1.31% | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $41.09M | $57.21M | $2.35M | $5.25M | (m) | 71.82% | 4.10% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |